Dopamine D1receptor signaling: Does GαQ-phospholipase C actually play a role?

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 9-17

  Lee, Sang Min ^a   Yang, Yang ^a   Mailman, Richard B ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4,5,5A,6,7,11B HEXAHYDRO 9,10 DIHYDROXY 2 PROPYL 3 THIA 5 AZACYCLOPENT 1 ENA[C]PHENANTHRENE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; ADENYLATE CYCLASE; APOMORPHINE; BENZAZEPINE DERIVATIVE; BETA ARRESTIN; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT Q; HETERODIMER; PERGOLIDE; PHOSPHOLIPASE C; ROTIGOTINE; SKF 82957; UNCLASSIFIED DRUG; SK&F 83959;

BINDING AFFINITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; HISTORY OF MEDICINE; LIGAND BINDING; MOLECULAR DYNAMICS; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; HUMAN; METABOLISM;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; DOPAMINE AGONISTS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; RECEPTORS, DOPAMINE D1; SIGNAL TRANSDUCTION; TYPE C PHOSPHOLIPASES;

EID: 84907170120     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214411     Document Type: Review

References (111)

1. Andringa G, Drukarch B, Leysen JE, Cools AR, and Stoof JC (1999a) The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. Eur J Pharmacol 364:33-41.
2. Andringa G, Stoof JC, and Cools AR (1999b) Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology (Berl) 146:328-334.
3. Arnsten AF, Cai JX, Murphy BL, and Goldman-Rakic PS (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 116:143-151.
4. Arnt J, Hyttel J, and Sánchez C (1992) Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213:259-267.
5. Asin KE and Wirtshafter D (1993) Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression. Eur J Pharmacol 235:167-168.
6. Aubert I, Ghorayeb I, Normand E, and Bloch B (2000) Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. J Comp Neurol 418:22-32.
7. Banday AA and Lokhandwala MF (2007) Oxidative stress reduces renal dopamine D1 receptor-Gq/11alpha G protein-phospholipase C signaling involving G proteincoupled receptor kinase 2. Am J Physiol Renal Physiol 293:F306-F315.
8. Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, and Greengard P (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11:932-939.
9. Bertran-Gonzalez J, Herve D, Girault JA, and Valjent E (2010) What is the degree of segregation between striatonigral and striatopallidal projections? Front Neuroanat 4:136 DOI: 10.3389/fnana.2010.00136.
10. Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, and Chase TN (1998) Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol 21:339-343.
11. Cai JX and Arnsten AF (1997) Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther 283:183-189.
12. Chemel BR, Bonner LA, Watts VJ, and Nichols DE (2012) Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D1 receptor catechol agonists. Mol Pharmacol 81:729-738.
13. Chun LS, Free RB, Doyle TB, Huang XP, Rankin ML, and Sibley DR (2013) D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms. Mol Pharmacol 84:190-200.
14. Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Jr, Bates MD, and Caron MG (1990) Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347:72-76.
15. Demchyshyn LL, Sugamori KS, Lee FJ, Hamadanizadeh SA, and Niznik HB (1995) The dopamine D1D receptor. Cloning and characterization of three pharmacologically distinct D1-like receptors from Gallus domesticus. J Biol Chem 270:4005-4012.
16. Deng YP, Lei WL, and Reiner A (2006) Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling. J Chem Neuroanat 32:101-116.
17. Deveney AM and Waddington JL (1995) Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Br J Pharmacol 116:2120-2126.
18. Diaz Heijtz R and Castellanos FX (2006) Differential effects of a selective dopamine D1-like receptor agonist on motor activity and c-fos expression in the frontalstriatal circuitry of SHR and Wistar-Kyoto rats. Behav Brain Funct 2:18.
19. Downes RP and Waddington JL (1993) Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopaminesensitive adenylyl cyclase. Eur J Pharmacol 234:135-136.
20. Dyck LE (1990) Effects of dopamine on phosphoinositide hydrolysis in slices of rat striatum and cortex. Neurochem Int 17:77-82.
21. Felder CC, Blecher M, and Jose PA (1989a) Dopamine-1-mediated stimulation of phospholipase C activity in rat renal cortical membranes. J Biol Chem 264: 8739-8745.
22. Felder CC, Jose PA, and Axelrod J (1989b) The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. J Pharmacol Exp Ther 248:171-175.
23. Friedman E, Butkerait P, and Wang HY (1993) Analysis of receptor-stimulated and basal guanine nucleotide binding to membrane G proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 214:171-178.
24. Friedman E, Jin LQ, Cai GP, Hollon TR, Drago J, Sibley DR, and Wang HY (1997) D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. Mol Pharmacol 51:6-11.
25. Fujita S, Kiguchi M, Kobayashi M, Kinsella A, Koshikawa N, and Waddington JL (2010) Assessment of jaw movements by magnetic sensor in relation to topographies of orofacial behaviour in freely moving rats: studies with the dopamine D1-like receptor agonists SKF 83822 vs SKF 83959. Eur J Pharmacol 632:39-44.
26. Garau L, Govoni S, Stefanini E, Trabucchi M, and Spano PF (1978) Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci 23:1745-1750.
27. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Jr, and Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432.
28. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, and Marsden CD (1995a) Differential anti-Parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology (Berl) 117:275-286.
29. Gnanalingham KK, Hunter AJ, Jenner P, and Marsden CD (1995b) Stimulation of adenylate cyclase activity by benzazepine D1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat-relationship to circling behaviour. Biochem Pharmacol 49:1185-1193.
30. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, and Williams GV (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174:3-16.
31. Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, and Taber MT (2001) Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. J Pharmacol Exp Ther 296:338-344.
32. Guo L, Zhao J, Jin G, Zhao B, Wang G, Zhang A, and Zhen X (2013) SKF83959 is a potent allosteric modulator of sigma-1 receptor. Mol Pharmacol 83:577-586.
33. Harrison MB, Wiley RG, and Wooten GF (1990) Selective localization of striatal D1 receptors to striatonigral neurons. Brain Res 528:317-322.
34. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O'Dowd BF, and George SR (2009) Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci USA 106: 21377-21382.
35. Hasbi A, O'Dowd BF, and George SR (2011) Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance. Mol Brain 4:26.
36. Huang X, Lawler CP, Lewis MM, Nichols DE, and Mailman RB (2001) D1 dopamine receptors. Int Rev Neurobiol 48:65-139.
37. Iorio LC, Barnett A, Leitz FH, Houser VP, and Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462-468.
38. Jin LQ, Goswami S, Cai G, Zhen X, and Friedman E (2003) SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem 85:378-386.
39. Kebabian JW and Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93-96.
40. Kebabian JW, Petzold GL, and Greengard P (1972) Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor". Proc Natl Acad Sci USA 69:2145-2149.
41. Kelly E, Batty I, and Nahorski SR (1988) Dopamine receptor stimulation does not affect phosphoinositide hydrolysis in slices of rat striatum. J Neurochem 51: 918-924.
42. Kenakin T (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28:407-415.
43. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, and Morita S (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336.
44. Kimura K, Sela S, Bouvier C, Grandy DK, and Sidhu A (1995) Differential coupling of D1 and D5 dopamine receptors to guanine nucleotide binding proteins in transfected GH4C1 rat somatomammotrophic cells. J Neurochem 64:2118-2124.
45. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
46. Le Moine C and Bloch B (1995) D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 355:418-426.
47. Lee SM, Kant A, Blake D, Murthy V, Boyd K, Wyrick SJ, and Mailman RB (2014) SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C. Neuropharmacology DOI: 10.1016/j.neuropharm.2014.05.042 [published ahead of print].
48. Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lança AJ, O'Dowd BF, and George SR (2004) Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279:35671-35678.
49. Lewis MM, Watts VJ, Lawler CP, Nichols DE, and Mailman RB (1998) Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther 286:345-353.
50. Liu J, Wang F, Huang C, Long LH, Wu WN, Cai F, Wang JH, Ma LQ, and Chen JG (2009a) Activation of phosphatidylinositol-linked novel D1 dopamine receptor contributes to the calcium mobilization in cultured rat prefrontal cortical astrocytes. Cell Mol Neurobiol 29:317-328.
51. Liu J, Wang W, Wang F, Cai F, Hu ZL, Yang YJ, Chen J, and Chen JG (2009b) Phosphatidylinositol-linked novel D1 dopamine receptor facilitates long-term depression in rat hippocampal CA1 synapses. Neuropharmacology 57:164-171.
52. Mahan LC, Burch RM, Monsma FJ, Jr, and Sibley DR (1990) Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca21 mobilization in Xenopus oocytes. Proc Natl Acad Sci USA 87:2196-2200.
53. Mailman RB (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28:390-396.
54. Mailman RB and Huang X (2007) Dopamine receptor pharmacology, in Parkinson's Disease and Related Disorders, Part 1 (Koller WC and Melamed E eds) pp 77-105, Elsevier, New York.
55. Mailman R, Huang X, and Nichols DE (2001) Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs 2:1582-1591.
56. Mailman RB and Murthy V (2010) Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 16:488-501.
57. Mailman RB and Nichols DE (1998) Dopamine D1 receptor agonists as antiparkinson drugs. Trends Pharmacol Sci 19:255-256.
58. Mailman RB, Nichols DE, Lewis MM, Blake BL, and Lawler CP (1998) Functional effects of novel dopamine ligands: dihydrexidine and Parkinson's disease as a first step, in Dopamine Receptor Subtypes: From Basic Science to Clinical Application (Jenner P and Demirdemar R eds) pp 64-83, IOS Stockton Press, Amsterdam.
59. Matamales M, Bertran-Gonzalez J, Salomon L, Degos B, Deniau JM, Valjent E, Hervé D, and Girault JA (2009) Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS One 4:e4770.
60. Medvedev IO, Ramsey AJ, Masoud ST, Bermejo MK, Urs N, Sotnikova TD, Beaulieu JM, Gainetdinov RR, and Salahpour A (2013) D1 dopamine receptor coupling to PLCb regulates forward locomotion in mice. J Neurosci 33:18125-18133.
61. Mizuno K, Kurokawa K, and Ohkuma S (2012) Dopamine D1 receptors regulate type 1 inositol 1,4,5-trisphosphate receptor expression via both AP-1- and NFATc4- mediated transcriptional processes. J Neurochem 122:702-713.
62. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, and Wightman RM, et al. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178.
63. Neumeyer JL, Kula NS, Bergman J, and Baldessarini RJ (2003) Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol 474: 137-140.
64. Neve KA (2009) Functional Selectivity of G Protein-Coupled Receptor Ligands, Humana, New York.
65. Neve KA, Seamans JK, and Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205.
66. O'Sullivan GJ, Roth BL, Kinsella A, and Waddington JL (2004) SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography. Eur J Pharmacol 486:273-280.
67. Pacheco MA and Jope RS (1997) Comparison of [3H]phosphatidylinositol and [3H]phosphatidylinositol 4,5-bisphosphate hydrolysis in postmortem human brain membranes and characterization of stimulation by dopamine D1 receptors. J Neurochem 69:639-644.
68. Panchalingam S and Undie AS (2001) SKF83959 exhibits biochemical agonism by stimulating [35S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40:826-837.
69. Pedersen UB, Norby B, Jensen AA, Schiodt M, Hansen A, Suhr-Jessen P, Scheideler M, Thastrup O, and Andersen PH (1994) Characteristics of stably expressed human dopamine D1a and D1b receptors: atypical behavior of the dopamine D1b receptor. Eur J Pharmacol 267:85-93.
70. Perreault ML, Fan T, Alijaniaram M, O'Dowd BF, and George SR (2012) Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2. PLoS One 7: e33348.
71. Perreault ML, Hasbi A, Alijaniaram M, Fan T, Varghese G, Fletcher PJ, Seeman P, O'Dowd BF, and George SR (2010) The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem 285:36625-36634.
72. Perreault ML, Hasbi A, O'Dowd BF, and George SR (2011) The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in basal ganglia. Front Neuroanat 5:31.
73. Perreault ML, Hasbi A, O'Dowd BF, and George SR (2014) Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. Neuropsychopharmacology 39:156-168.
74. Popper K (1959) The Logic of Scientific Discovery, Routledge Classics (2002 Reissue), London.
75. Rappaport MS, Sealfon SC, Prikhozhan A, Huntley GW, and Morrison JH (1993) Heterogeneous distribution of D1, D2 and D5 receptor mRNAs in monkey striatum. Brain Res 616:242-250.
76. Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, and Wright S, et al. (1999) ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 45:736-741.
77. Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, and Thalamas C, et al. (2001) Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58:249-254.
78. Rashid AJ, O'Dowd BF, Verma V, and George SR (2007a) Neuronal Gq/11-coupled dopamine receptors: an uncharted role for dopamine. Trends Pharmacol Sci 28: 551-555.
79. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O'Dowd BF, and George SR (2007b) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 104:654-659.
80. Rosell DR, Zaluda LC, McClure MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, and Abi-Dargham A, et al. (2014) Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacol, in press.
81. Rubinstein JE and Hitzemann RJ (1990) Further evidence against the coupling of dopamine receptors to phosphoinositide hydrolysis in rat striatum. Biochem Pharmacol 39:1965-1970.
82. Ryman-Rasmussen JP, Griffith A, Oloff S, Vaidehi N, Brown JT, Goddard WA, 3rd, and Mailman RB (2007) Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors. Neuropharmacology 52:562-575.
83. Ryman-Rasmussen JP, Nichols DE, and Mailman RB (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol 68:1039-1048.
84. Schneider JS, Sun ZQ, and Roeltgen DP (1994) Effects of dihydrexidine, a full dopamine D1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res 663:140-144.
85. Scibilia RJ, Lachowicz JE, and Kilts CD (1992) Topographic nonoverlapping distribution of D1 and D2 dopamine receptors in the amygdaloid nuclear complex of the rat brain. Synapse 11:146-154.
86. Setler PE, Sarau HM, Zirkle CL, and Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419-430.
87. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, and Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
88. Shenoy SK and Lefkowitz RJ (2005) Seven-transmembrane receptor signaling through b-arrestin. Sci STKE 2005:cm10.
89. Starr MS (1996) The role of dopamine in epilepsy. Synapse 22:159-194.
90. Steele TD, Hodges DB, Jr, Levesque TR, and Locke KW (1997) D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats. Pharmacol Biochem Behav 58:477-483.
91. Steele TD, Hodges DB, Jr, Levesque TR, Locke KW, and Sandage BW, Jr (1996) The D1 agonist dihydrexidine releases acetylcholine and improves cognition in rats. Ann N Y Acad Sci 777:427-430.
92. Taylor JR, Lawrence MS, Redmond DE, Jr, Elsworth JD, Roth RH, Nichols DE, and Mailman RB (1991) Dihydrexidine, a full dopamine D1 agonist, reduces MPTPinduced parkinsonism in monkeys. Eur J Pharmacol 199:389-391.
93. Toda M and Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9:329-336.
94. Trifilieff P, Rives ML, Urizar E, Piskorowski RA, Vishwasrao HD, Castrillon J, Schmauss C, Slättman M, Gullberg M, and Javitch JA (2011) Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques 51:111-118.
95. Undie AS and Friedman E (1990) Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J Pharmacol Exp Ther 253:987-992.
96. Undie AS and Friedman E (1992) Selective dopaminergic mechanism of dopamine and SKF38393 stimulation of inositol phosphate formation in rat brain. Eur J Pharmacol 226:297-302.
97. Undie AS and Friedman E (1994) Inhibition of dopamine agonist-induced phosphoinositide hydrolysis by concomitant stimulation of cyclic AMP formation in brain slices. J Neurochem 63:222-230.
98. Undie AS, Weinstock J, Sarau HM, and Friedman E (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem 62:2045-2048.
99. Urban JD, Clarke WP, von ZastrowM, Nichols DE, Kobilka B, WeinsteinH, Javitch JA, Roth BL, Christopoulos A, and Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
100. Urizar E, Yano H, Kolster R, Galés C, Lambert N, and Javitch JA (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Chem Biol 7:624-630.
101. Urs NM, Daigle TL, and Caron MG (2011) A dopamine D1 receptor-dependent b-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 36:551-558.
102. Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, and Stoof JC (1994) The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 9:664-672.
103. Vyas SJ, Eichberg J, and Lokhandwala MF (1992) Characterization of receptors involved in dopamine-induced activation of phospholipase-C in rat renal cortex. J Pharmacol Exp Ther 260:134-139.
104. Wallace MA and Claro E (1990) A novel role for dopamine: inhibition of muscarinic cholinergic-stimulated phosphoinositide hydrolysis in rat brain cortical membranes. Neurosci Lett 110:155-161.
105. Weinstock J, Hieble JP, and Wilson JW (1985) The chemistry and pharmacology of 3-benzazepine derivatives. Drugs Future 10:645-696.
106. Yu PY, Eisner GM, Yamaguchi I, Mouradian MM, Felder RA, and Jose PA (1996) Dopamine D1A receptor regulation of phospholipase C isoform. J Biol Chem 271: 19503-19508.
107. Yu Y, Wang JR, Sun PH, Guo Y, Zhang ZJ, Jin GZ, and Zhen X (2008) Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 b and a receptorindependent anti-oxidative action. J Neurochem 104:946-956.
108. Zhang H, Ma L, Wang F, Chen J, and Zhen X (2007) Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDAlesioned rat model of Parkinson's disease. Neuropharmacology 53:125-133.
109. Zhang X, Zhou Z, Wang D, Li A, Yin Y, Gu X, Ding F, Zhen X, and Zhou J (2009) Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca21 signaling. J Neurosci 29:7766-7775.
110. Zhang ZJ, Jiang XL, Zhang SE, Hough CJ, Li H, Chen JG, and Zhen XC (2005) The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm. Neurosci Lett 382:134-138.
111. Zhen X, Goswami S, and Friedman E (2005) The role of the phosphatidyinositollinked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol Biochem Behav 80:597-601 Footnotes.